EUVIMEDEUVIMED entdecken
Crossref

Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation

Roberta Fenoglio, Savino Sciascia, Dario Roccatello

Journal of the American Society of Nephrology · 2026-10 · 37 (10S)

DOI: 10.1681/asn.202644e83yca ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026-10. Verfasst von Roberta Fenoglio und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Fenoglio, R., Sciascia, S., & Roccatello, D. (2026). Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation. Journal of the American Society of Nephrology, 37(10S). https://doi.org/10.1681/asn.202644e83yca

Vancouver

Fenoglio R, Sciascia S, Roccatello D. Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation. Journal of the American Society of Nephrology. 2026;37(10S). doi:10.1681/asn.202644e83yca

BibTeX
@article{Fenoglio2026,
  author = {Fenoglio, Roberta and Sciascia, Savino and Roccatello, Dario},
  title = {Daratumumab Monotherapy vs. Bortezomib-Based Regimen in Frail Patients with Renal AL Amyloidosis Ineligible for Kidney Transplantation},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {10S},
  doi = {10.1681/asn.202644e83yca}
}
Kostenlos starten →